World's Best Scientists 2026 revealed!
Paul J. Kurtin

Paul J. Kurtin

D-Index & Metrics

Medicine

D-Index
89
Citations
25169
World Ranking
12815
National Ranking
6549

Overview

Paul J. Kurtin is affiliated with the Mayo Clinic in the United States and has a research focus primarily in medicine and biochemistry, genetics, and molecular biology. Their body of work spans key subfields such as molecular biology, pathology and forensic medicine, genetics, oncology, and nephrology.

The scientist's research extensively covers clinical and molecular aspects of amyloidosis and lymphoma diagnosis and treatment. Their main topics of study include:

  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Lymphoma Diagnosis and Treatment
  • Parathyroid Disorders and Treatments
  • Peptidase Inhibition and Analysis
  • Cancer-related Gene Regulation
  • Neuroendocrine Tumor Research Advances
  • Dermatological and Skeletal Disorders

Recent notable publications include:

  • "Systemic amyloidosis from A (AA) to T (ATTR): a review" (2020, Journal of Internal Medicine)
  • "Amyloid Typing by Mass Spectrometry in Clinical Practice: a Comprehensive Review of 16,175 Samples" (2020, Mayo Clinic Proceedings)
  • "Association between spinal stenosis and wild-type ATTR amyloidosis" (2021, Amyloid)
  • "Striking Association of Lymphoid Enhancing Factor (LEF1) Overexpression and DUSP22 Rearrangements in Anaplastic Large Cell Lymphoma" (2020, The American Journal of Surgical Pathology)
  • "High level MYC amplification in B-cell lymphomas: is it a marker of aggressive disease?" (2020, Blood Cancer Journal)

Frequent co-authors in their scholarly work are:

  • Ellen D. McPhail
  • Surendra Dasari
  • Jason D. Theis
  • Karen L. Rech
  • Angela Dispenzieri

The venues where Kurtin has most regularly published include:

  • Amyloid
  • Human Pathology
  • The American Journal of Surgical Pathology
  • Blood Cancer Journal
  • Journal of Internal Medicine

This profile reflects a focused expertise in the clinical and molecular pathology related to amyloidosis and lymphoma, supported by a consistent pattern of contributions in relevant peer-reviewed journals and collaborations with other researchers in adjacent fields.

Best Publications

  • Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

    Robert A. Kyle;Ellen D. Remstein;Terry M. Therneau;Angela Dispenzieri

  • The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma

    Kerry J. Savage;Stefano Monti;Jeffery L. Kutok;Giorgio Cattoretti

  • Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

    Stefano Monti;Kerry J. Savage;Jeffery L. Kutok;Friedrich Feuerhake

  • Lymphoid Neogenesis in Rheumatoid Synovitis

    Seisuke Takemura;Andrea Braun;Cynthia Crowson;Paul J. Kurtin

  • Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma

    Thomas E. Witzig;Susan M. Geyer;Irene Ghobrial;David J. Inwards

  • Epithelial membrane antigen--a diagnostic discriminant in surgical pathology: immunohistochemical profile in epithelial, mesenchymal, and hematopoietic neoplasms using paraffin sections and monoclonal antibodies.

    Geraldine S. Pinkus;Paul J. Kurtin

  • The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis.

    Janet E. Olson;Carol A. Janney;Ravi D. Rao;James R. Cerhan

  • Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

    Matthew J. Maurer;Hervé Ghesquières;Hervé Ghesquières;Jean Philippe Jais;Thomas E. Witzig

  • Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study.

    Jane N. Winter;Edie A. Weller;Sandra J. Horning;Maryla Krajewska

  • BLyS and APRIL in rheumatoid arthritis

    Thorsten M. Seyler;Yong W. Park;Yong W. Park;Seisuke Takemura;Richard J. Bram

  • NFκB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes

    Friedrich Feuerhake;Jeffery L. Kutok;Stefano Monti;Wen Chen

  • Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas.

    Ellen D. Remstein;C. David James;Paul J. Kurtin

  • Leukocyte common antigen—a diagnostic discriminant between hematopoietic and nonhematopoietic neoplasms in paraffin sections using monoclonal antibodies: Correlation with immunologic studies and ultrastructural localization

    Paul J. Kurtin;Geraldine S. Pinkus

  • Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas

    Andrew L. Feldman;Mark Law;Ellen D. Remstein;William R. Macon

  • Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas.

    William R. Macon;Norman B. Levy;Paul J. Kurtin;Kevin E. Salhany

  • Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type.

    Paul Kurtin;Jeffrey Myers;Hakiran Adlakha;John Strickler

  • The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America.

    Ellen D. Remstein;Ahmet Dogan;Richard R. Einerson;Sarah F. Paternoster

  • Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects.

    Suhail Ahmad;H. Thomas Robertson;Thomas A. Golper;Marsha Wolfson

  • Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: A phase II trial in the north central cancer treatment group

    Thomas E. Witzig;Allen M. Vukov;Thomas M. Habermann;Susan Geyer

  • Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.

    Stephen M. Ansell;David J. Inwards;Kendrith M. Rowland;Patrick J. Flynn

Frequent Co-Authors

Thomas E. Witzig
Thomas E. Witzig Mayo Clinic
Ahmet Dogan
Ahmet Dogan Memorial Sloan Kettering Cancer Center
Surendra Dasari
Surendra Dasari Mayo Clinic
David J. Inwards
David J. Inwards Mayo Clinic
Curtis A. Hanson
Curtis A. Hanson Mayo Clinic
Samih H. Nasr
Samih H. Nasr Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring ways to enter or advance in the medical field, there are a variety of flexible online degree programs and career pathways worth considering. For instance, students interested in administrative roles might look at the medical billing and coding financial aid options available, which help make these programs more accessible and affordable.

Nursing is another popular path, and you may wonder: do you have to take the teas test to get into nursing school? Some accredited nursing schools offer admission without the typical standardized entrance exams, removing barriers for aspiring nurses.

For those aiming for leadership roles, an accelerated healthcare administration degree can quickly prepare you for managerial careers in hospitals, clinics, and beyond.

Registered nurses aiming to become nurse practitioners can consider structured adn to np bridge programs available online, which fast-track career progression without sacrificing work experience.

Each of these options provides a unique route into the healthcare industry, offering flexibility, financial support, and opportunities for advancement.

Best Scientists Citing Paul J. Kurtin

Trending Scientists

Recently Published Articles